JMJonathan C. Morris

Jonathan C. Morris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan C. Morris has a total of 374 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    XFM and HERFD-XAS studies of selenium in tissues and whole blood from mice supplemented with potentially therapeutic selenocompounds

    by Ani T. Baker, Tamara Ortiz-Cerda, Kangzhe Xie, Jordan Hunter, Iliya Dragutinovic, Jonathan C. Morris, Linda I. Vogt, Graham N. George, Dimosthenis Sokaras, Daryl L. Howard, et al.

    Selenium nanoparticles (SeNPs) and selenoneine (SeN) are prospective nutritional supplements and therapeutic agents postulated to counteract Se deficiency and alleviate oxidative stress induced by various pathological conditions. X-ray fluorescence microscopy (XFM) and high energy resolution fluorescence detected X-ray absorption spectroscopy (HERFD-XAS) investigated Se distribution and speciation in mice fed supranutritional doses of SeNPs (10 mg Se/kg in feed) and SeN (5 mg Se/kg in feed). Mice fed control and SeNP diets showed equivalent Se distributions in the liver and testes, however, Se concentrations were elevated in the renal tubules of mice supplemented with SeNPs. Negligible differences in the composition of selenospecies were detected in tissues from mice fed SeNPs and control diets. Mice supplemented with SeN exhibited significant elevations in Se across all analysed tissues. Se Kα1 HERFD-XAS data revealed reduced SeN as the predominant selenospecies in tissues and blood from mice fed the SeN diet. Characterisation of the SeN-enriched feed showed that SeN was initially present in both the oxidised dimer and reduced monomer forms. These results support the hypothesised in vivo reduction of SeN and subsequent bioaccumulation in the blood and various tissues. The present findings highlight marked differences in the bioavailability and utilisation of these purported therapeutic selenocompounds.


  • Epoxidation-Enhanced Charge-Switch Derivatization for Rapid Profiling of Monounsaturated Fatty Acid Isomers

    by Sarah E. Hancock, Linda Garthwaite, Laura L. Y. Choong, Iliya Dragutinovic, Jonathan C. Morris, Nigel Turner

    Structural isomerism in monounsaturated fatty acids (MUFAs) presents a persistent challenge in lipidomics due to limited chromatographic resolution and indistinguishable mass spectral profiles. Moreover, many methods that overcome these limitations require specialized instruments or additional apparatus that are typically not available for those using standard lipidomics core facilities. We report a streamlined LC-MS/MS method that integrates N-(4-aminomethylphenyl)pyridinium (AMP)-based charge-switch derivatization with meta-chloroperoxybenzoic acid (mCPBA) epoxidation to enable rapid and sensitive profiling of MUFA double bond positional isomers. Charge-switching enables enhanced detection of fatty acids, while epoxidation improves chromatographic resolution and produces diagnostic fragmentation patterns upon collision-induced dissociation (CID), enabling precise localization of double bond positions. The optimized workflow achieves baseline separation of 16:1, 18:1, and 20:1 MUFA isomers within a 20 min gradient, with reproducible retention times and consistent epoxide yields. The method also supports partial resolution of polyunsaturated fatty acids (PUFA) and cis/trans isomers. Application to prostate cancer cell lines revealed distinct MUFA isomer profiles associated with aberrant fatty acid desaturase 2 (FADS2) activity, including elevated n-10 and n-12 isomers in tumorigenic lines. These results align with prior studies using other isomer-resolving techniques, validating the method's analytical performance. This accessible and robust strategy expands the toolkit for lipidomics research, providing a method that is compatible with conventional LC-MS/MS workflows, positioning it as a practical solution for high-resolution isomer analysis in complex biological samples.


  • The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease

    by Sohni Ria Bhalla, Mussarat Wahid, Jason O Amartey, Amira Zawia, Federica Riu, Yizhuo Gao, Jyoti Agrawal, Amy P Lynch, Maria Jc Machado, Tom Hawtrey, et al.

    Introduction. In peripheral arterial disease (PAD) anti-angiogenic VEGF-A165b isoform overexpression in monocytes contributes to impaired collateralisation. Serine-arginine protein-kinase-1 (SRPK1) regulates VEGF splicing. To determine whether SRPK1 controlled monocytic VEGF, impairing collateralisation, we investigated SRPK1 inhibition and monocyte-specific knockout in mouse models of and in human monocytes from PAD. Methods. VEGF-A165b activity was measured by co-culture of PAD patients‘ monocytes with endothelial cells with SRPK1 inhibition. Mice with impaired revascularisation due to soluble-frizzled-related-protein-5 knockout (Sfrp5-/-), monocyte-specific Wnt5a gain-of-function (LysM-Wnt5aGOF), or obese mice on a high-fat high-sucrose (HF/HS) diet were subjected to femoral artery ligation and treated with SRPK1 inhibitor. We generated an SRPK1 conditional knockout and crossed it with monocyte-specific (LysM-Cre) driver line to specifically knockout SRPK1 in monocyte lineages. Blood flow was measured by Laser Speckle Imaging before, and for 28 days after surgery. Results. Monocytes from PAD patients significantly inhibited endothelial cell migration, which was reversed by an anti-VEGF-A165b antibody. Surprisingly, migration was stimulated by SRPK1 inhibition, switching splicing from VEGF-A165b to VEGF-A165a. In Sfrp5-/-, LysM-Wnt5aGOF and HF/HS mouse models of PAD, blood flow was improved by SRPK1 inhibition. Impaired revascularisation in LysM52 Wnt5aGOF mice was rescued in LysM-Wnt5aGOF:SRPK1MoKO mice, which had a phenotypic shift towards M2 macrophages. Impaired blood flow recovery was also rescued in obese-SRPK1MoKO mice. Conclusion. VEGF splicing in monocytes is regulated differently from VEGF splicing in epithelial or cancer cells suggesting that control of splicing is dependent on cell type and/or environment. SRPK1 inhibition enhances collateralisation in mice, and in human in vitro models of monocyte-dependent impaired angiogenesis.


  • Open Access

    Correction: Inhibition of CERS1 in skeletal muscle exacerbates age-related muscle dysfunction

    by Martin Wohlwend, Pirkka-Pekka Laurila, Ludger Je Goeminne, Tanes Imamura de Lima, Ioanna Daskalaki, Xiaoxu Li, Giacomo von Alvensleben, Barbara Crisol, Renata Mangione, Hector Gallart-Ayala, et al.

    One of the analyses in the final paper comprises C. elegans skeletal muscle morphology experiments upon Cers1 inhibition (Figure 4E). This experiment was conducted by Amélia Lalou at École Polytechnique Fédérale de Lausanne (EPFL). During the review process, Amélia Lalou was accidentally removed from the author list. We are therefore formally correcting the eLife paper to include Amélia Lalou in the author list. She has reviewed the manuscript, supports the conclusion and agrees to be responsible for all the parts of the paper in its published form. All authors have agreed to the change.


  • Open Access

    The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease

    by Sohni Ria Bhalla, Mussarat Wahid, Jason O Amartey, Amira Zawia, Federica Riu, Yizhuo Gao, Jyoti Agrawal, Amy P Lynch, Maria Jc Machado, Tom Hawtrey, et al.

    Introduction: In peripheral arterial disease (PAD) anti-angiogenic VEGF-A 165 b isoform overexpression in monocytes contributes to impaired collateralisation. Serine-arginine protein-kinase-1 (SRPK1) regulates VEGF splicing. To determine whether SRPK1 controlled monocytic VEGF, impairing collateralisation, we investigated SRPK1 inhibition and monocyte-specific knockout in mouse models of and in human monocytes from PAD. Methods: VEGF-A 165 b activity was measured by co-culture of PAD patients’ monocytes with endothelial cells with SRPK1 inhibition. Mice with impaired revascularisation due to soluble-frizzled-related-protein-5 knockout (Sfrp5 -/- ), monocyte-specific Wnt5a gain-of-function (LysM-Wnt5a GOF ), or obese mice on a high-fat high-sucrose (HF/HS) diet were subjected to femoral artery ligation and treated with SRPK1 inhibitor. We generated an SRPK1 conditional knockout and crossed it with monocyte-specific (LysM-Cre) driver line to specifically knockout SRPK1 in monocyte lineages. Blood flow was measured by Laser Speckle Imaging before, and for 28 days after surgery. Results: Monocytes from PAD patients significantly inhibited endothelial cell migration, which was reversed by an anti-VEGF-A 165 b antibody. Surprisingly, migration was stimulated by SRPK1 inhibition, switching splicing from VEGF-A 165 b to VEGF-A 165 a. In Sfrp5 -/- , LysM-Wnt5a GOF and HF/HS mouse models of PAD, blood flow was improved by SRPK1 inhibition. Impaired revascularisation in LysM-Wnt5a GOF mice was rescued in LysM-Wnt5a GOF :SRPK1 MoKO mice, which had a phenotypic shift towards M2 macrophages. Impaired blood flow recovery was also rescued in obese-SRPK1 MoKO mice. Conclusion: VEGF splicing in monocytes is regulated differently from VEGF splicing in epithelial or cancer cells suggesting that control of splicing is dependent on cell type and/or environment. SRPK1 inhibition enhances collateralisation in mice, and in human in vitro models of monocyte-dependent impaired angiogenesis. New and Noteworthy: A novel potential treatment for peripheral arterial disease (PAD) is described. Inhibition of SRPK1, or knockout in monocytes, induces angiogenesis by preventing splicing to anti-angiogenic VEGF (VEGF-A 165 b) in patients and animal models. In PAD, monocyte splicing control is different from other cell types and SRPK1 inhibition by drug like compounds can alter macrophage phenotype and reverse PAD in mice using a new cell specific SRPK1-LoxP mouse.


  • Open Access

    Inhibition of CERS1 in skeletal muscle exacerbates age-related muscle dysfunction

    by Martin Wohlwend, Pirkka-Pekka Laurila, Ludger Je Goeminne, Tanes Lima, Ioanna Daskalaki, Xiaoxu Li, Giacomo von Alvensleben, Barbara Crisol, Renata Mangione, Hector Gallart-Ayala, et al.

    Age-related muscle wasting and dysfunction render the elderly population vulnerable and incapacitated, while underlying mechanisms are poorly understood. Here, we implicate the CERS1 enzyme of the de novo sphingolipid synthesis pathway in the pathogenesis of age-related skeletal muscle impairment. In humans, CERS1 abundance declines with aging in skeletal muscle cells and, correlates with biological pathways involved in muscle function and myogenesis. Furthermore, CERS1 is upregulated during myogenic differentiation. Pharmacological or genetic inhibition of CERS1 in aged mice blunts myogenesis and deteriorates aged skeletal muscle mass and function, which is associated with the occurrence of morphological features typical of inflammation and fibrosis. Ablation of the CERS1 orthologue lagr-1 in Caenorhabditis elegans similarly exacerbates the age-associated decline in muscle function and integrity. We discover genetic variants reducing CERS1 expression in human skeletal muscle and Mendelian randomization analysis in the UK biobank cohort shows that these variants reduce muscle grip strength and overall health. In summary, our findings link age-related impairments in muscle function to a reduction in CERS1, thereby underlining the importance of the sphingolipid biosynthesis pathway in age-related muscle homeostasis.


  • Open Access

    Mitochondrial electron transport chain, ceramide, and coenzyme Q are linked in a pathway that drives insulin resistance in skeletal muscle

    by Alexis Diaz-Vegas, Søren Madsen, Kristen C Cooke, Luke Carroll, Jasmine Xy Khor, Nigel Turner, Xin Y Lim, Miro A Astore, Jonathan C Morris, Anthony S Don, et al.

    Insulin resistance (IR) is a complex metabolic disorder that underlies several human diseases, including type 2 diabetes and cardiovascular disease. Despite extensive research, the precise mechanisms underlying IR development remain poorly understood. Previously we showed that deficiency of coenzyme Q (CoQ) is necessary and sufficient for IR in adipocytes and skeletal muscle (Fazakerley et al., 2018). Here, we provide new insights into the mechanistic connections between cellular alterations associated with IR, including increased ceramides, CoQ deficiency, mitochondrial dysfunction, and oxidative stress. We demonstrate that elevated levels of ceramide in the mitochondria of skeletal muscle cells result in CoQ depletion and loss of mitochondrial respiratory chain components, leading to mitochondrial dysfunction and IR. Further, decreasing mitochondrial ceramide levels in vitro and in animal models (mice, C57BL/6J) (under chow and high-fat diet) increased CoQ levels and was protective against IR. CoQ supplementation also rescued ceramide-associated IR. Examination of the mitochondrial proteome from human muscle biopsies revealed a strong correlation between the respirasome system and mitochondrial ceramide as key determinants of insulin sensitivity. Our findings highlight the mitochondrial ceramide–CoQ–respiratory chain nexus as a potential foundation of an IR pathway that may also play a critical role in other conditions associated with ceramide accumulation and mitochondrial dysfunction, such as heart failure, cancer, and aging. These insights may have important clinical implications for the development of novel therapeutic strategies for the treatment of IR and related metabolic disorders.


  • Open Access

    Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion

    by Mussarat Wahid, Benjamart Pratoomthai, Isioma U. Egbuniwe, Hannah R. Evans, Roya Babaei-Jadidi, Jason O. Amartey, Viola Erdelyi, Kiren Yacqub-Usman, Andrew M. Jackson, Jonathan C. Morris, et al.

    Background: Regulation of alternative splicing is a new therapeutic approach in cancer. The programmed cell death receptor 1 (PD-1) is an immunoinhibitory receptor expressed on immune cells that binds to its ligands, PD-L1 and PD-L2 expressed by cancer cells forming a dominant immune checkpoint pathway in the tumour microenvironment. Targeting this pathway using blocking antibodies (nivolumab and pembrolizumab) is the mainstay of anti-cancer immunotherapies, restoring the function of exhausted T cells. PD-1 is alternatively spliced to form isoforms that are either transmembrane signalling receptors (flPD1) that mediate T cell death by binding to the ligand, PD-L1 or an alternatively spliced, soluble, variant that lacks the transmembrane domain. Methods: We used PCR and western blotting on primary peripheral blood mononuclear cells (PBMCs) and Jurkat T cells, IL-2 ELISA, flow cytometry, co-culture of melanoma and cholangiocarcinoma cells, and bioinformatics analysis and molecular cloning to examine the mechanism of splicing of PD1 and its consequence. Results: The soluble form of PD-1, generated by skipping exon 3 (∆Ex3PD1), was endogenously expressed in PBMCs and T cells and prevents cancer cell-mediated T cell repression. Multiple binding sites of SRSF1 are adjacent to PD-1 exon 3 splicing sites. Overexpression of phosphomimic SRSF1 resulted in preferential expression of flPD1. Inhibition of SRSF1 phosphorylation both by SRPK1 shRNA knockdown and by a selective inhibitor, SPHINX31, resulted in a switch in splicing to ∆Ex3PD1. Cholangiocarcinoma cell-mediated repression of T cell IL-2 expression was reversed by SPHINX31 (equivalent to pembrolizumab). Conclusions: These results indicate that switching of the splicing decision from flPD1 to ∆Ex3PD1 by targeting SRPK1 could represent a potential novel mechanism of immune checkpoint inhibition in cancer.


  • Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy

    by Naseeb K. Malhi, Claire L. Allen, Elizabeth Stewart, Katherine L. Horton, Federica Riu, Jennifer Batson, Winfried Amoaku, Jonathan C. Morris, Kenton P. Arkill, David O. Bates

    Angiogenic VEGF isoforms are upregulated in diabetic retinopathy (DR), driving pathological growth and fluid leakage. Serine-arginine-rich protein kinase-1 (SRPK1) regulates VEGF splicing, and its inhibition blocks angiogenesis. We tested the hypothesis that SRPK1 is activated in diabetes, and an SRPK1 inhibitor (SPHINX31) switches VEGF splicing in DR and prevents increased vascular permeability into the retina. SRPK1 was activated by high glucose (HG), in a PKC-dependent manner, and was blocked by SPHINX31. HG induced release of SRSF1 from the nuclear speckles, which was also SRPK1 dependent, and increased retinal pigment epithelial (RPE) monolayer admittance, which was reversed by SRPK1 inhibition (P < 0.05). Diabetes increased retinal permeability and thickness after 14 days which was blocked by treatment with SPHINX31 eye drops (P < 0.0001). These results show that SRPK1 inhibition, administered as an eye drop, protected the retinal barrier from hyperglycemia-associated loss of integrity in RPE cells in vitro and in diabetic rats in vivo. A clinical trial of another SRPK1 inhibitor has now been initiated in patients with diabetic macular edema. NEW & NOTEWORTHY VEGF-A165b splicing is induced by hyperglycemia through PKC-mediated activation of SRPK1 in RPE cells, increasing their permeability and angiogenic capability. SRPK1 inhibitors can be given as eye drops to reduce retinal permeability and edema in diabetic retinopathy. Listen to this article’s corresponding podcast at https://ajpheart.podbean.com/e/srpk1-eye-drops-as-a-treatment-for-diabetic-retinopathy/.


  • Open Access

    Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma

    by Ryan J Duchatel, Abdul Mannan, Ameha S Woldu, Tom Hawtrey, Phoebe A Hindley, Alicia M Douglas, Evangeline R Jackson, Izac J Findlay, Zacary P Germon, Dilana Staudt, et al.

    Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brainstem tumor for which radiation is the only treatment. Case studies report a clinical response to ONC201 for patients with H3K27M-mutant gliomas. Oncoceutics (ONC201) is only available in the United States and Japan; however, in Germany, DIPG patients can be prescribed and dispensed a locally produced compound—ONC201 German-sourced ONC201 (GsONC201). Pediatric oncologists face the dilemma of supporting the administration of GsONC201 as conjecture surrounds its authenticity. Therefore, we compared GsONC201 to original ONC201 manufactured by Oncoceutics Inc. Authenticity of GsONC201 was determined by high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. Biological activity was shown via assessment of on-target effects, in vitro growth, proliferation, and apoptosis analysis. Patient-derived xenograft mouse models were used to assess plasma and brain tissue pharmacokinetics, pharmacodynamics, and overall survival (OS). The clinical experience of 28 H3K27M+ mutant DIPG patients who received GsONC201 (2017–2020) was analyzed. GsONC201 harbored the authentic structure, however, was formulated as a free base rather than the dihydrochloride salt used in clinical trials. GsONC201 in vitro and in vivo efficacy and drug bioavailability studies showed no difference compared to Oncoceutics ONC201. Patients treated with GsONC201 (n = 28) showed a median OS of 18 months (P = .0007). GsONC201 patients who underwent reirradiation showed a median OS of 22 months compared to 12 months for GsONC201 patients who did not (P = .012). This study confirms the biological activity of GsONC201 and documents the OS of patients who received the drug; however, GsONC201 was never used as a monotherapy.